Schedule For Drug Fee Estimates Slips As IRS Revises Guidance
Executive Summary
The Internal Revenue Service has pushed back some of the implementation deadlines for the new market-share based fees on drug manufacturers by a couple of weeks to accommodate issues raised in response to its November guidance.